Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 1 – Gastrointestinal tumours, colorectal

4839 - Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases- A single center randomized control trial


28 Sep 2019


Proffered Paper 1 – Gastrointestinal tumours, colorectal


Clinical Research

Tumour Site

Colon and Rectal Cancer


Jianmin Xu


Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394


J. Xu1, T. Liu2, W. Tang1, W. Chang3, Q. Feng1, Y. Wei1, L. Ren1, Q. Ye4, Y. Cui2, G. He1, T. Liu1, D. Zhu1, M. Ji1

Author affiliations

  • 1 General Surgery, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
  • 2 Medical Oncology, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
  • 3 General Surgery, Zhongshan Hospital, Fudan University, 200010 - shanghai/CN
  • 4 Liver Surgery, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4839


To assess the effects of bevacizumab plus chemotherapy as first-line treatment for RAS mutant unresectable colorectal liver metastases (CLMs).


From June 2013 to December 2017, patients with RAS mutant unresectable liver-limited metastases from colorectal cancer were randomly assigned to receive chemotherapy (mFOLFOX6 [modified fluorouracil, leucovorin,and oxaliplatin]) plus bevacizumab (arm A) or chemotherapy alone (arm B). The resectability of liver metastases was determined by a local multidisciplinary team. The primary end point was the rate of patients converted to resection for liver metastases. Secondary end points included tumor response, survival and toxicity. Block randomization method was used.


The intent-to-treat population comprised 241 patients. 121 patients were randomly assigned to arm A and 120 to arm B. For all patients, 35.7% (86/241) had right-sided colon cancer; 47.3% (114/241) had primary tumour resection before randomization; 86.3% (208/241) had liver metastases more than three; 33.2 (80/241) with the diameter of liver metastases more than 5 cm; 78.4% (189/241) were bilobar metastases. The median follow-up time was 37.0 months for all patients. The R0 resection rates for liver metastases were 22.3% (27 of 121 patients) in arm A and 5.8% (7 of 120 patients) in arm B, with significant difference (P < 0.01). Patients in arm A had significantly better objective response rates (54.5% v 36.7%; P < 0.01), median PFS (9.5 v 5.6 months; P < 0.01) and median OS (25.7 v 20.5 months; P = 0.03) compared with those in arm B. Addition of bevacizumab was associated with more frequent proteinuria(9.9% v 3.3%; P = 0.04) and hypertension ( 8.3% v 2.5%; P < 0.05).


For patients with initially unresectable RAS mutant CLMs, bevacizumab combined with chemotherapy improved the resectability of liver metastases and improved response rates and survival compared with chemotherapy alone.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Zhongshan Hospital.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.